中段前肾上腺髓质素在中重度主动脉瓣狭窄中的新型预测作用
研究纳入173例中重度主动脉瓣狭窄且NYHA I-II级、LVEF≥50%的患者,检测六种循环生物标志物,用竞争风险分析评估预后预测能力。中位随访期间主要和次要结局分别发生59例(34%)和66例(38%)。MR-proADM对主要结局(SHR 11.3,95%CI 3.9-32.7)和次要结局(SHR 12.6,95%CI 4.7-33.5)的区分能力最高,可能成为AS风险分层的首选生物标志物。
要点
- MR-proADM对中重度AS患者主要和次要结局的预测区分度最高。
- MR-proADM联合hsTnT或NT-proBNP为最佳预测模型。
- 双标志物模型不优于MR-proADM单标志物模型。
核心结论
- MR-proADM对中重度主动脉瓣狭窄患者的不良预后具有最强预测价值。
- MR-proADM应进一步评估作为AS风险分层的可能首选生物标志物。
研究设计与样本
- 多中心连续入组173例中重度AS患者,NYHA I-II级,LVEF≥50%,2011-2018年招募。
- 检测NT-proBNP、hsTnT、GDF-15、ST2、MR-proADM和MR-proANP六种生物标志物。
- 采用竞争风险分析评估对主要和次要结局的预测能力,主动脉瓣置换作为竞争风险。
主要发现
- 主要结局发生59例(34%),次要结局发生66例(38%)。
- 除ST2外,合并症指数和每种选定生物标志物均一致预测主要结局(p<0.05),独立于NYHA分级、Vmax、LV-GLS和血肌酐。
- MR-proADM对主要结局的SHR为11.3(95%CI 3.9-32.7),对次要结局的SHR为12.6(95%CI 4.7-33.5)。
- MR-proADM联合hsTnT或NT-proBNP为最佳预测模型,但双标志物模型不优于MR-proADM单标志物模型。
关键数值与推荐
- 患者年龄69±11岁,男性55%,峰值跨主动脉流速(Vmax)4.0±0.8 m/s。
- 主要结局:全因死亡、心衰住院或进展至NYHA III-IV级;次要结局另加晕厥和急性冠脉综合征。
- MR-proADM对主要结局SHR 11.3(95%CI 3.9-32.7),对次要结局SHR 12.6(95%CI 4.7-33.5)。
临床怎么用
- 对中重度AS且症状轻微、LVEF保留的患者,可检测MR-proADM以辅助风险分层。
- MR-proADM升高可能提示不良预后风险增加,需加强监测和考虑干预时机。
- MR-proADM单标志物预测价值不劣于联合hsTnT或NT-proBNP的双标志物模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated the prognostic significance of selected known and novel circulating biomarkers in aortic stenosis (AS). METHODS: N-terminal pro-BNP (NT-proBNP), high-sensitivity troponin-T (hsTnT), growth differentiation factor-15 (GDF-15), suppression of tumorigenicity-2 (ST2), mid-regional proadrenomedullin (MR-proADM) and mid-regional proatrial natriuretic peptide (MR-proANP) were measured in patients with moderate to severe AS, New York Heart Association (NYHA) class I-II and left ventricular ejection fraction ≥50%, recruited consecutively across five centres from 2011 to 2018. Their ability to predict both primary (all-cause mortality, heart failure hospitalisation or progression to NYHA class III-IV) and secondary (additionally incorporating syncope and acute coronary syndrome) outcomes was determined by competing risk analyses. RESULTS: Among 173 patients with AS (age 69±11 years, 55% male, peak transaortic velocity (Vmax) 4.0±0.8 m/s), the primary and secondary outcomes occurred in 59 (34%) and 66 (38%), respectively. With aortic valve replacement as a competing risk, the primary outcome was determined consistently by the comorbidity index and each selected biomarker except ST2 (p<0.05), independent of NYHA class, Vmax, LV-global longitudinal strain and serum creatinine. MR-proADM had the highest discriminative value for both primary (subdistribution HR (SHR) 11.3, 95% CI 3.9 to 32.7) and secondary outcomes (SHR 12.6, 95% CI 4.7 to 33.5). Prognostic assessment of dual-biomarker combinations identified MR-proADM plus either hsTnT or NT-proBNP as the best predictive model for both clinical outcomes. Paired biomarker models were not superior to those including MR-proADM as the sole circulating biomarker. CONCLUSION: MR-proADM most powerfully portended worse prognosis and should be further assessed as possibly the biomarker of choice for risk stratification in AS.
引用
- Tan, Oon, Chan, et al. Novel predictive role for mid-regional proadrenomedullin in moderate to severe aortic stenosis. Heart. 2022. PMID: 35332049. doi:10.1136/heartjnl-2021-320707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。